SPECTROSCOPIC INVESTIGATIONS OF BINDING MECHANISMS BETWEEN ANTIMICROBIAL PEPTIDES AND MODELS OF THE MEMBRANES OF PSEUDOMONAS AERUGINOSA AND KLEBSIELLA PNEUMONIAE by Chai, Hanbo
Abstract 
SPECTROSCOPIC INVESTIGATIONS OF BINDING MECHANISMS BETWEEN 
ANTIMICROBIAL PEPTIDES AND MODELS OF THE MEMBRANES OF 
PSEUDOMONAS AERUGINOSA AND KLEBSIELLA PNEUMONIAE 
by 
Hanbo Chai 
June 2014 
Major Department: Chemistry 
Department Chair: Dr. Allison S. Danell 
Director of Thesis: Dr. Rickey P. Hicks 
The wide application of antibiotics goes back over sixty years to the first use of 
penicillin in the mid-1940s. Antimicrobial agents have well-documented activity and have 
played a significant role in defending against various bacterial infections. However, antibiotic 
resistance has never ceased to undermine the efficacy of those compounds and has become a 
severe threat to patients with serious infections. It is imperative to discover and develop 
antibacterial agents with novel action mechanisms to lower the chance of drug resistance. A 
wide series of compounds called “antimicrobial peptides” (AMPs) have been either 
discovered in the nature or synthesized in laboratories around the world. The advent of AMPs 
has brought a new hope in the fight against the rise of antibiotic-resistant organisms. 
Far-UV Circular Dichroism (CD) spectroscopy and 1H NMR have been used to 
investigate the interactions of a series of synthetic, unnatural amino acid-containing AMPs 
with Lipopolysaccharide (LPS) isolated from drug resistant Gram-negative bacteria 
Pseudomonas aeruginosa and Klebsiella pneumoniae, along with various phospholipid 
compositions to better approximate the chemical makeup of the membranes of these two 
strains. The results showed that: (1) the binding interactions between the AMPs and the 
membranes are defined by the physicochemical properties of the peptide and the membrane 
model; (2) binding of these AMPs to the lipid A region (the innermost and phospholipid-like 
layer) of the LPS is stronger and dominant compared with the binding with the 
O-polysaccharide outer leaf moiety; (3) when different compositions of phospholipids were 
incorporated into the LPS to make a complete membrane model of the two strains, 
wavelength shifts in the CD spectra of the AMPs were observed that represents 
conformational changes of AMPs upon binding with the membrane model. 
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CHAPTER 1: BACKGROUND INFORMATION 
1.1 Drug Resistant Bacteria：Evolution and Medical Issues 
1.1.1 A Brief History of Drug Resistant Evolution 
Drug resistance of bacteria is not a recent phenomenon, having accompanied almost the 
entire history of antibiotics discovery and development. Dating back to 1937, the 
sulfonamides were applied as the first generation of antimicrobial treatments and shortly 
thereafter drug resistance specific to sulfonamides was observed [1]. Before the introduction 
of sulfonamides, the most famous and widely used antibiotic, penicillin, was discovered by 
the future Nobel laureate Sir Alexander Fleming. Several years after 1940 this β-lactam 
compound had saved millions of people’s lives who had war wounds and other infections in 
World War II [2]. However, this powerful antibiotic was not resistance-free even at the 
primitive stage of therapeutic application. Before penicillin was formally introduced as an 
antibacterial agent, an enzyme which can deactivate and degrade penicillin was discovered 
and identified in some bacteria species including Balantidium coli [3]. This observation 
suggested that resistance had naturally existed among the bacterial population before large 
scale antibiotic application made it so apparent. 
    Throughout the history of antibiotic discovery and development, there are several 
important time points [1]. Penicillinase was discovered at almost the same time with 
penicillin during early 1940s; the golden age began in the 1950s when a large number of 
antibiotics were found, identified and used. This group of drugs also primarily formed the 
modern arsenal still used today. The advent of molecular biology in the 1960s facilitated a 
molecular level understanding of the role of drug resistance genes found in bacterial genomes, 
  
but drug-resistant genomes imbedded in bacterial genomes became to be selected and 
enhanced by various antibiotics at an increasing speed since then [1]. Important research 
methods, such as pharmacologic, biochemical, target enzyme specific and more recent 
genomic HTS (High Throughout Sequencing) have worked together to improve the use of 
antibiotics by modifying dosing, understanding drug resistance mechanisms, designing new 
compounds and predicting potential antibiotic action targets [1]. Another time point worth 
mentioning is the establishment of the FDA Office of New Drugs after the famous 
pharmaceutical scandal caused by the notorious teratogen thalidomide, making the new drug 
registration much stricter and slower. Meanwhile, during the years from the late 1960s to 
2000, drug resistance increased significantly due to heavy use of those compounds. The rapid 
advancements of synthetic chemistry made the industrial large-scale production a less 
challenging process and remarkably lowered the price of those compounds. People 
manufactured them easily, and underuse, overuse, and misuse contributed significantly to the 
acceleration of gene mutations and the selection of resistant strains [1]. 
1.1.2 Drug Resistant Bacteria of Medical Significance 
Infectious human diseases bacteria have turned into multidrug-resistant (MDR) forms as 
a result of inappropriate antibiotic use [1]. An important MDR pathogen is 
multidrug-resistant tuberculosis (MDR-TB), which is known for being resistant to 
isoniazid (INH) and rifampicin (RMP), two major first-line anti-TB drugs [4]. There are 
several medically significant bacterial strains of interest, including Enterococcus faecium, S. 
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, 
Enterobacter species, know collectively as ESKAPE for abbreviation [5]. 
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Among the ESKAPE, Enterococcus faecium and S. aureus are Gram-positive bacteria. 
Gram-positive bacteria are characteristized by a thick, porous cross-linked peptidoglycan 
layer on the top of cytoplasmic lipid layer [6]. Enterococcus faecium can be either innocuous, 
existing in human gastrointestinal tract, or be pathogenic, when found in surgical wound 
infection and urinary tract infection in hospitals [7]. When being multidrug-resistant, 
especially to vancomycin, it is referred to VRE [8]. S. aureus is a widely distributed 
bacterium that commonly infects human respiratory tract. This bacterium has notorious fame 
throughout infection treatment history, ranging from pimples to lethal pneumonia, toxic 
shock syndrome and sepsis. It is one of the major nonsocomial infections and American 
hospitals alone treat approximately 500,000 patients every year for staphylococcal infection 
[9]. S. aureus had developed high percentage of in-hospital resistance to penicillin after only 
fifteen years of wide application of the antibiotic [10]. The greatest threat brought by S. 
aureus is know as MRSA, or Methicillin-resistant S. aureus, which can be resistant to most 
β-lactam antibiotics. MRSA is now a problem in hospitals. Unfortunately there are only 
several families of antibiotics, such as glycopeptides antibiotic vancomycin, can treat MRSA 
with a relatively good outcome. However, even vancomycin is not the permanent standing 
line since recently MRSA isolates associated with decreased susceptibility to glycopeptides 
have been reported [11]. 
    By comparison, the membrane structure of Gram-negative bacteria is more complex due 
to its lipopolysaccharide (LPS)-containing outer membrane. A peptidoglycan layer is still 
present but is much thinner than that of Gram-positive bacteria, lying between an LPS outer 
membrane and plasma membrane. LPS is an amphiphilic molecule that consists of three parts: 
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a highly variable hydrophile O-antigen, core oligosaccharide, and highly conserved 
hydrophobic lipid A [12]. The sugar sequence of O-antigen can vary from strain to strain [13]. 
The infections brought by Gram-negative bacteria can be severe because LPS is an endotoxin 
that can bind with cell types of the human immune system to induce a strong immune 
response, promoting the excessive release of cytokines and consequently causing septic shock 
[14]. Therefore it’s more challenging to treat Gram-negative bacterial infections and extra 
attention should be paid to those with multidrug resistance. 
    On our bacterial interest list, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa and Enterobacter species are Gram-negative. It is no surprise all of 
the four have developed multidrug resistance and become major causes of many nosocomial 
infections [15]. Acinetobacter baumannii is well known in military units, and its multidrug 
resistance spread into civilian hospitals because of transportation of wounded soldiers [16]. 
Enterobacter is an opportunistic pathogen which infects hospitalized, immunocompromised 
patients with urinary tract infections (UTIs), intra-abdominal infections, endocarditis, etc. 
Pseudomonas aeruginosa and Klebsiella pneumoniae are focus of this thesis project. The 
former is typically opportunistic and nosocomial, naturally has a wide spectrum of antibiotic 
resistance, and causes a series of hospital-acquired infections including pneumonia, septic 
shock, urinary tract infection, and gastrointestinal tract infection. Patients with cystic fibrosis, 
skin burns, and premature infants are always highly endangered groups [17]. Lastly, 
Klebsiella pneumoniae causes deadly Klebsiella pneumonia, which gradually damages the 
human lungs through inflammation and hemorrhage. Severe cell death and so-called “currant 
jelly sputum” are the results. Immunocompromised patients are more susceptible to this 
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infection.  
1.2 Potential Solution to Drug Resistance: Antimicrobial Peptides (AMP) 
    The wide application of antibiotics has been going on for over sixty years since the first 
use of penicillin. Those antimicrobial agents have well-documented activity and have played 
a significant role in defending against various bacterial infections. However, antibiotic 
resistance continues to undermine the efficacy of those compounds and has become a severe 
threat to patients with serious infections. As previously stated, the fast growth of antibiotic 
resistance during the later half of the 20th century is a result of human selection by abusing 
and misusing traditional antibiotics [1].  
The specificity of traditional antibiotics can be a double-edged sword; specificity allows 
one antibiotic to be active against one or a similar series of microorganisms using a unique 
mechanism of action. For instance, penicillin belongs to the family of β-lactam antibiotics, 
which inhibit peptidoglycan sythesis of bacteria cell wall. This target-specificity makes the 
antibacterial spectrum clear-cut and makes the choice of treatment straightforward. However, 
specificity can also be a limitation. Penicillinase was actually discovered and identified as a 
force of defense produced by the pathogen earlier than the medical application of the 
antibiotic itself [1]. This type of attack-and-defense relationship widely exists in nature. But 
again, the inappropriate and large-scale use of antibiotics during the past six decades has 
facilitated the evolution of resistance genes which make pathogens much more difficult to 
deal with. Vancomycin, widely regarded as “the last standing line against the severe 
infections”, has been used to treat serious MRSA infections. But resistant S. aureus specific 
to vancomycin appeared in Japan in 1997 as vancomycin-intermediate S. aureus (VISA) [20] 
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and in 2002 a higher level resistant strain was reported in Michigan, USA [21] as 
vancomycin-resistant S. aureus (VRSA). This example strongly supports the old Chinese 
proverb: “While the priest climbs a post, the devil climbs ten”. This war between traditional 
antibiotics and rapidly evolving pathogens will continue, and the later could win if antibiotics 
have no revolutionary step forward. 
Therefore it is imperative to discover and develop antibacterial agents with novel action 
mechanisms to minimize the chance of drug resistance. To this end, a wide series of 
compounds called “antimicrobial peptides” (AMP) have been either discovered in nature or 
synthesized in laboratories around the world. The advent of AMPs has brought new hope to 
the fight against the rise of antibiotic-resistant organisms.  
The earliest publication record of antimicrobial peptides can be traced back to the 1980s. 
Researchers injected bacteria into the pupae of the cecropia moth, and later on a 37 amino 
acid cationic peptide was isolated and purified from the hemolymph of the moth. 
Biosynthesis of this peptide was induced by the injected bacteria and the peptide showed 
antibacterial activity against multiple Gram-negative bacteria including Escherichia coli and 
Pseudomonas aeruginosa [18]. 
    The discovery of the moth peptide was followed by another important study, in which a 
series of peptides were found in the granules of human and rabbit granulocytes. The 
molecules featured 29 to 34 amino acids, of which six cysteine residues were highly 
conserved and involved in intramolecular disulfide bond. Shortly after, they were found to be 
active against both gram-negative and gram-positive bacteria [18].  
These two events are among many milestones throughout the discovery and 
 6 
 
development history of antimicrobial peptides. Since a great number of those peptides show 
remarkable in vitro activity against bacteria with single or multiple resistances to traditional 
antibiotics, they possess great potential to become templates for anti-infectious drug design 
[19]. The common structural features of an antimicrobial peptide include positive charge and 
amphipathicity. They are cationic (at least 3+) due to an unusual abundance of lysine and 
arginine residues. Being amphipathic allows water-solubility and lipid layer-compatibility at 
the same time. Length ranges from 12 to 45 amino acid residues [22]. Natural occurring 
antimicrobial peptides generally adopt four classes of structures: α-helix, β-strand, extended 
coil and loop [22]. 
Many of those peptides can adopt different conformations when they are placed in 
different chemical environments and their antimicrobial activities can be correlated with the 
changes in conformations. The investigation of human cathelicidin LL-37 is a good example. 
In aqueous solutions such as phosphate buffer, circular dichroism (CD) spectroscopy shows 
the compound to lack secondary structure. By comparison, when in trifluoroethanol, sodium 
dodecyl sulphate (SDS) micelles, or phospholipid, partially or all α-helix conformation is 
present. Furthermore, the percentage of α-helicity is coupled to the antibacterial activity. 
Increased α-helical content correlates with stronger antimicrobial activities [24].  
Several important characteristics of the peptide structure will affect activity and 
specificity, including amino acid sequence, charge density, hydrophobicity and 
amphipathicity. Those characteristics and their roles are listed in table 1.1 [24]. 
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Table 1.1: Important structural characteristics of cationic antimicrobial peptides [24] 
Characteristic Role in peptide structure and conformation 
Size 12 to 45 amino acid residues in length. Should not be too short in order 
to adopt proper conformation; Di- and tripeptides with ntimicrobial 
activity have been reported. 
Conformation and 
structure 
Various conformations, but three of them are major: α-helices, relaxed 
coils and antiparallel β-sheet structures. Generally for natural 
antimicrobial peptides, amphipathic α-helical peptides are often more 
active than peptides with less-defined secondary structures. 
Charge Cationic due to high percentage of lysine or arginine. Highly cationic 
peptides are often more active than neutral peptides or those with a 
lower charge. 
Sequence Basic amino acid residues lysine or arginine should be included in order 
to keep the peptide cationic; hydrophobicity can be achieved by 
incorporating residues alanine, leucine, phenylalanine or tryptophan. 
Hydrophobicity Necessary for antimicrobial peptides to partition into the membrane lipid 
bilayer. Aromatic and hydrophobic ring in phenylalanine or tryptophan 
is crucial to this structural feature. 
Amphipathicity Hydrophilic residues along one side to make them water-soluble and 
hydrophobic residues along the opposite side to have effective 
interactions with lipid bilayer. 
Admittedly, more-potent traditional antibiotics still serve as main-stream anti-infection 
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agents, but antimicrobial peptides have many intriguing advantages, including an ability to 
more rapidly kill target cells, unusually broad inhibitory activity spectra, activity against 
some of the more serious antibiotic-resistant pathogens, and a relative difficulty in selecting 
resistant mutation genes in vitro, which is vital to confront the issue of rising 
antibiotic-resistance [19].  
    
1.3 Background of the Project 
1.3.1 De novo Design of antimicrobial peptides incorporating unnatural amino acids 
    Design of new peptides from individual amino acids is a very challenging process, 
especially when non-RNA encoded, unnatural amino acids are present in the peptide 
sequence. Compared to standard organic synthesis, the design of antimicrobial peptides 
would be very difficult without the aid of three-dimensional physicochemical models and 
almost impossible starting from random design by hand [56]. Two methods can be used, at 
the onset of the design process: molecular modeling techniques, or adapting known naturally 
occurring antimicrobial peptides with well-documented structure and antibacterial activities.  
    Our model compound is an analog of magainin-2 amide, Ala8, 13, 18 magainin-2 amide. It 
has three Ala residues at the position of 8, 13 and 18, respectively. It was chosen for its 
potent activity against both Gram-positive and Gram-negative bacteria and minimal 
interaction with mammalian cells [28]. The specificity can be explained by the difference of 
peptide-membrane interaction mechanisms. For eukaryotic cells, like erythrocytes, the 
membrane is zwitterionic. For bacterial cells, the membrane is often anionic [25]. Therefore a 
successful design should enable the peptide to interact effectively with anionic cell (bacteria) 
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membranes while zwitterionic cell membranes (mammalian animals) should stay intact [56]. 
    In the study of Ala8, 13, 18 magainin-2, DPC micelles and SDS micelles serve as models 
of zwitterionic lipids and anionic lipids, respectively [26]. Two-dimensional NMR and 
molecular modeling were used to investigate the interaction behavior of Ala8, 13, 18 magainin-2 
with DPC and SDS micelles. Two-dimensional NMR indicates that Ala8, 13, 18 magainin-2 
amide, when binding to DPC micelles, adopts an α-helical conformation involving residues 
2–16. The four C-terminal residues converge to a loose β-turn structure. When incorporated 
into SDS micelles, however, Ala8, 13, 18 magainin-2 amide adopts a β-helical conformation 
involving residues 7–18. The C- and N-terminal residues exhibit a great deal of 
conformational flexibility. Calculations were performed based on the information provided 
by two-dimensional NMR, generating electrostatic surface potential maps (ESP) for the 
different conformers of magainin-2 bound with DPC and Ala8, 13, 18 magainin-2 bound with 
DPC or SDS. The results indicate that antimicrobial peptides adopt different conformations 
when they are bound to zwitterionic and anionic micelle models and consequently interact 
with the two models via different mechanisms [26]. The NMR and molecular modeling 
studies suggest that for any particular antimicrobial peptide, potency and selectivity are 
controlled by the chemical composition (zwitterionic or anionic) of the target cell’s 
membrane [27].  
    Based on the studies above the design process begins with several critical factors taken 
into consideration, including secondary structure, molecular flexibility between regions of 
limited conformational flexibility, overall molecular charge distribution, charge density, and 
charge clusters [24]. Starting from the N-terminus, a so-called “N-capping residue” initiates 
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the peptide chain and this residue is usually a neutral amino acid. The 2nd residue is often a 
natural amino acid which is either positively charged (Arg or Lys) or hydrophobic (Phe for 
the most cases). This residue is critical for defining the physicochemical character of the 
N-terminus. The next come the 3rd and 4th residues, both of which are unnatural amino acids 
forming a conformationally restrained dipeptide unit. In this study the two unnatural amino 
acids are Tic (tetrahydroisoquinolinecarboxylic acid) and Oic (octahydroindolecarboxylic 
acid), respectively [56] (Figure 1.1). The peptide skeleton design process can be very 
complex but there are several key moieties to be mentioned. Spacer 1 controls the overall 
conformational flexibility of the molecule, which can be adjusted by arying the number of 
–CH2- group within; spacer 2 defines the relative distance between the peptide back bone and 
the membrane surface and the distance between peptide backbone and positively charged 
residue as well; The dipeptide unit controls local secondary structure, reduces the flexibility 
of the peptide backbone and induces a potential turn structure [56]. For the most cases in our 
peptides, the hydrophobic residue is phenylalanine or its derivatives. Assembling those 
elements together in a logical sequence comes up with a pool of peptides shown in Table 1.2. 
The design process does not belong to this thesis project thus it is only briefly discussed for 
back ground information. Frequently used unnatural amino acids are also shown in Figure 
1.1. 
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 SPACER 3
SPACER 2 
SPACER 1 
SPACER 2
R=N terminus-Phe-Gly-Ac 
n=1, 2, 3, 4, 5 
SPACER 1
 
                        
 
 Oic (Octahydro-1H-isoindole-1-carboxylic acid) TiC (Tetrahydroisoquinoline-3-carboxylic acid) 
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 Dpr (2,3-diaminopropanoic acid) GABA (4-amino butyric acid) Dab (2,4-diaminobutanoic acid)
 
Orn (ornithine) 
Figure 1.1: A basic skeleton representation of AMPs developed by Hicks et al [56] and 
structures of frequently used amino acids 
Table 1.2: Selected novel antimicrobial peptides used in this study [5] [28] 
Peptide # Amino acid sequence 
23 Ac-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK-CONH2 
29 Ac-Gaba-F-Tic-Oic-Gaba-K-Tic-Oic-Gaba-F-Tic-Oic-Gaba-K-Tic-KKKK-CONH2 
36 Ac-βAla-F-Tic-Oic-βAla-K-Tic-Oic-βAla-F-Tic-Oic-βAla-K-Tic-KKKK-CONH2 
39 Ac-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKKK-CONH2 
43 Ac-GF-Tic-Oic-G-Orn-Tic-Oic-GF-Tic-Oic-G-Orn-Tic-Orn-Orn-Orn-Orn-CONH2 
46 Ac-βAla-Fpa-Tic-Oic-βAla-Dpr-Tic-Oic-βAla-Fpa-Tic-Oic-βAla-Dpr-Tic-Dpr-Dpr-Dp
r-Dpr-CONH2 
53 Ac-GF-Tic-Oic-G-Dab-Tic-Oic-GF-Tic-Oic-G-Dab-Tic-Dab-Dab-Dab-Dab-CONH2 
56 Ac-GF-Tic-Oic-GR-Tic-Oic-GF-Tic-Oic-GR-Tic-RRRR-CONH2 
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1.3.2 Objectives of the Project 
Cell lysis mediated by an AMP is believed to occur by insertion of the AMP into the cell 
membrane followed by disruption of the membrane. Most structure-activity relationship 
studies used various zwitterionic and anionic phospholipids compositions as membrane 
models for bacterial membranes [29] [30]. This idea has worked well for Gram-positive 
bacteria which contain a single phospholipid membrane. However, this approach does not 
accurately model AMPs’ interactions with the membranes of Gram-negative bacteria [31]. 
The outer membrane of Gram-negative bacteria contains a high percentage of 
lipopolysaccharides (LPS) on the surface of the membrane [32]. The chemical composition of 
LPS varies by bacteria strain and consists of three components [33]. The outer most 
component is the highly variable polysaccharide chain known as the O-antigen, the second 
component consists of the core oligosaccharide unit and the inner most component consists of 
the highly conserved, phospholipid-like lipid A, a polyacylated glucosamine-based 
bis-phospholipid [34]. LPS is highly negatively charged and functions as a semipermeable 
membrane that modulates the transport of AMPs across the bacteria membrane. LPS is also 
known as an endotoxin after release from the membrane [33]. These endotoxins are potent 
inducers of the innate immune system and thus cause the uncontrolled release of cytokines 
resulting in septic shock, leading to a series of lethal consequences including organ damage. 
Therefore, in the case of Gram-negative bacteria, it is of the same importance to understand 
the physicochemical interactions that occur between an AMP and LPS as well as the 
physicochemical properties of AMPs and the phospholipids components of the cell 
membranes in order to facilitate the new drug design of potential AMPs with remarkable 
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antibacterial activity against Gram-negative bacteria. 
There have been previous reports on the in vitro activity of a series of synthetic AMPs 
that exhibited diverse inhibition activity toward Pseudomonas aeruginosa and Klebsiella 
pneumoniae [5]. These AMPs exhibited greater inhibitory activity against another 
Gram-negative bacteria Acinetobacter baumannii [5]. Therefore, the inhibitory activity of 
these AMPs must be defined by the interactions that occur between the AMPs and the various 
cell membrane components of different bacterial strains.  The intent of this project is to 
attempt correlating the physicochemical properties of these AMPs with the binding 
interactions observed for a series of the membrane models of Pseudomonas aeruginosa and 
Klebsiella pneumoniae. From this investigation we hope to better explain the observed in 
vitro inhibitory activity of these AMPs and help to provide useful information on new 
antimicrobial drug design.  
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CHAPTER 2: Experimental Details. 
    Deuterated sodium acetate, deuterated acetic acid and LPS were purchased from Sigma 
Aldrich. POPC, POPG and POPE were purchased from Avanti Polar Lipids (Purity >99%). 
All chemicals were used without additional purification. 
2.1 Sample Preparation 
2.1.1 Peptide synthesis 
The peptides were synthesized either by manual tBOC chemistry or by automated 
peptide synthesizer via FMOC chemistry [35] [36]. All peptides were purified by reverse 
phase HPLC using an Agilent 1100 series preparative instrument and a Vydac C18 reverse 
phase preparative HPLC column. Note: in this project the peptide synthesis process is not 
actually practiced because it’s been done previously [28]. Peptide solids are used directly and 
this part is for background information only. 
2.1.2 Preparation of mixed POPC/POPE/POPG SUVs 
The appropriate amount of dry POPC, POPG and POPE was weighted out to yield a 
final lipid concentration of 35 mM with the desired percentage of each phospholipid. The 
lipid was hydrated with 2 mL of buffer (40 mM sodium phosphate, pH = 6.8) and vortexed 
extensively. SUVs were prepared by sonication of the milky lipid suspension using a titanium 
tip ultra-sonicator (Qsonica Sonicators model Q55) for approximately 40 minutes in an ice 
bath until the solution became transparent. The titanium debris was removed by 
centrifugation at 8,800 rev./min for 10 minutes using an Eppendorf  table top centrifuge [37]. 
Final lipid concentration used for CD studies was 3.5 mM. 
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2.1.3 Preparation of LPS ONLY SUVs 
A 4 mg sample of the appropriate lipopolysaccharide was hydrated with 4 mL of buffer 
(40 mM sodium phosphate, pH = 6.8) and vortexed extensively. SUVs were prepared by 
sonication of the milky lipid suspension using a titanium tip ultra-sonicator (Qsonica 
Sonicators model Q55) for approximately 10 minutes at a temperature of 40 ℃ until the 
solution became transparent [38]. The titanium debris was removed by centrifugation at 8800 
rev/min for 10 minutes using an Eppendorf table top centrifuge. 
2.1.4 Preparation of LPS-mixed phospholipid SUVs 
5 mg sample of the lipopolysaccharide isolated from Klebsiella pnemoniae was mixed 
with 9.84 mg of POPC, 0.68 mg of POPG and 2.53 mg of POPE yielding a lipid composition 
of 75%POPC/5%POPG/20%POPE (molar ratio) or 5.07 mg sample of the lipopolysaccharide 
isolated from Pseudomonas  aeruginosa was mixed with 7.66 mg of POPC, 2.79 mg of 
POPG and 2.52 mg of POPE yielding a lipid composition of 59% POPC/21% POPG/20% 
POPE each preparation was then hydrated with 2 mL of buffer (40 mM sodium phosphate, 
pH = 6.8) and vortexed extensively. SUVs were prepared by sonication of the milky lipid 
suspension using a titanium tip ultra-sonicator (Qsonica Sonicators model Q55) for 
approximately 40 minutes in an ice bath until the solution became transparent. The titanium 
debris were removed by centrifugation at 8,800 rev./min for 10 minutes using an Eppendorf  
table top centrifuge [37]. A similar procedure was used by Matsuzaki and co-workers to 
prepare LPS-POPC SUVs [39]. 
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2.2 Circular Dichroism 
The peptide solutions were prepared weighing approximately 2 mg of peptide dissolved 
in 1.0 mL of phosphate buffer. For LPS-lipid SUV studies 100 μL of stock peptide solution 
was added to 20 μL of stock LPS-lipid solution with 80 μL of phosphate buffer. For lipid 
SUV studies 100 μL of stock peptide solution was added to 20 μL of stock lipid solution with 
80 μL of phosphate buffer. For LPS liposomes studies 350 μL of stock LPS solution was 
mixed with 50 μL of stock peptide solution. CD spectroscopy is very useful to monitor 
conformational changes in peptide. LPS can exhibit CD spectra but with careful subtraction 
of the LPS background meaningful spectra of the AMPs bound to the LPS can be obtained.  
All CD spectra were obtained by acquiring 8 scans (accumulation) on a JASCO J-815 
CD Spectrometer to achieve good S/N ratio. The signal to noise ratio (S/N) of a CD 
measurement is proportional to the square root of the number of scans and to the square root 
of the time constant [55]. Good S/N ratios can be achieved either by multiple fast scans 
recorded with a short time constant or by recording a small number of slow scans with a long 
time constant. A 0.1 mm cylindrical quartz cell (Starna Cells, Atascadero, CA) is used and a 
spectral width of 260 to 195 nm is selected to observe amide bond electrons absorption 
change [40] and thus the secondary structure change of the AMPs can be investigated. 
Spectra were collected using the following parameters, scan rate 20 nm/min, 1 nm bandwidth, 
data pitch 0.2 nm, response time 2.0 sec and 5 mdeg sensitivity at room temperature. The 
spectral bandwidth is generally set to 1 nm. The data pitch determines the number of data 
points taken during the scan, i.e., number of data points per nm, will not directly influence the 
noise level. However if post run data processing will be applied to reduce the noise, it’s 
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recommended to collect as many data points as possible to increase the efficiency of the post 
run filtering algorithm [55]. Response time is also known as data integration time, which is 
generally 2 seconds. The product of scanning speed (20 nm/min) and response time (2.0 sec) 
should be less than 60 nm·min-1·sec [55]. If higher values are used there will be significant 
errors in both the positions and intensities of the observed CD bands. 
    Contributions due to liposomes or LPS were eliminated by subtracting the lipid or LPS 
spectra of the corresponding peptide-free solutions. All analysis of CD spectra will be 
conducted after smoothing (Gaussian function) using the JASCO Spectra Analysis program 
[40]. CD spectra that exhibited HT values of greater than 500 volt (V) (or 600 V for a less 
strict standard) will not be used because CD spectra will be seriously distorted if the 
photomultiplier voltage rises above this limit. 
 
 
 
 
 
 
 
 
 
 
 
 19 
 
CHAPTER 3: Results and Discussions 
3.1 Circular Dichroism (CD) Studies of AMPs Interacting with Three Liposome Systems 
3.1.1 Liposome System One: Lipopolysaccharide (LPS) Outer Membrane isolated from 
Gram-negative Bacteria Pseudomonas aeruginosa and Klebsiella pneumoniae 
From outermost to innermost there are three main components in the LPS monomer are 
the O-antigen, inner core oligosaccharide, and the phospholipid-like lipid A. The O-antigen is 
the most variable domain of LPS and the sugar moiety among different bacterial species. For 
instance, over 160 different O-antigen structures have been identified from different E. coli 
strains [33]. The core oligosaccharide is the first component outside the cell membrane 
between the O-antigen and lipid A and its sugar moiety is less variable than O-antigen. The 
core oligosaccharide usually contains sugars such as heptose and 
3-deoxy-D-mannooctulosonic acid (aka KDO, keto-deoxyoctulosonate). The KDOs are often 
phosphorylated. These KDOs and heptoses make up the "inner core" section [41]. The lipid A 
portion, from which the LPS molecule actually “grows” and projects from cell membrane, is 
the most conserved section within Gram-negative bacteria outer membrane structure. 
Chemically it consists of a glucosamine disaccharide unit which is phosphorylated and tailed 
with many kinds of fatty acids [43] [44]. A great portion of the toxicity of Gram-negative 
bacteria comes from the lipid A, since when bacterial cells are lysed by the immune system, 
fragments of membrane containing lipid A are released into the circulation, causing 
well-known fatal endotoxic shock (also called septic shock) [42].  
Unlike phospholipids, LPS has a significant negative single peak in CD spectra around 
185 to 200 nm due to the oligosaccharide headgroup [38]. The absorption wavelength 
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depends on the chemical composition of different bacterial strains. Therefore, for each 
distinct peptide-LPS CD study, preparation of pure LPS with the identical amount of lipid in 
buffer is necessary so that the LPS background signals can be subtracted in order to compare 
the conformational change of the peptide upon interacting with LPS liposomes [38]. 
    In the infection process, outer membrane LPS tends to form vesicles, which in complex 
fluids may resemble the physiological and chemical characteristics of the original bacterium 
[45]. Since the infection occurs under physiological conditions within host tissues, and Lipid 
A has a large amount of acyl chains just like other common phospholipids, it is logical for us 
to assume that under the experimental condition of LPS solution preparation previously 
mentioned, LPS from Pseudomonas aeruginosa and Klebsiella pneumoniae can form similar 
vesicles which resembles the natural outer membrane. 
    Since LPS is the first barrier that peptide molecules should contact with and migrate 
through when they interact with Gram-negative bacteria cell membrane [33], it is necessary 
to investigate the interaction between the peptide and the pure LPS and CD is a useful tool to 
monitor conformational changes of peptide from peptide alone in phosphate buffer and 
peptide-LPS complex. As previously stated in the experimental section, LPS liposome stock 
solution was prepared by extensive vortex and sonication in phosphate buffer according to 
the work by Brandenburg K. et al and it is believed that after vortex and sonication LPS may 
form multilayer vesicles [54], however, it is yet to be confirmed. For our project, though it 
still remains unclear what kind of vesicle the LPS may form under the said experimental 
condition, it’s still useful for providing a model system to study peptide-LPS interaction by 
CD spectroscopy. 
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Table 3.1: Lipopolysaccharides (LPS) and phospholipid compositions of the SUVs used 
in this project 
Model # Bacteria Strain Region of 
Membrane 
composition Abbreviation 
Klebsiella  
pneumoniae 
outer leaflet of 
outer membrane 
100% LPS LPS (K) 1 
Pseudomonas  
aeruginosa 
outer leaflet of 
outer membrane 
100% LPS LPS (K) 2 
Klebsiella    
pneumoniae  
outer membrane 
(complete) 
LPS /75% 
POPC/20%POPE/5% 
POPG  
LPS (K)-mix 
(K) 
3 
Pseudomonas  
aeruginosa 
outer membrane 
(complete) 
LPS/59% 
POPC/20% 
POPE/21% POPG 
LPS (P)-mix 
(P) 
4 
Klebsiella    
pneumoniae  
inner membrane 75% POPC/20% 
POPE/5% POPG 
Mix (K) 5 
Pseudomonas  
aeruginosa 
inner membrane 59% POPC/20% 
POPE/21% POPG 
Mix (P) 6 
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CD spectra of pure LPS and peptide (binding with LPS, LPS spectrum subtracted) 
 
 
Figure 3.1: (Top) CD spectra of LPS vesicle alone from Pseudomonas aeruginosa (P) and 
Klebsiella pneumoniae (K) in phosphate buffer, where the buffer baseline has been subtracted 
from the original spectrum. Since the molecular weight of LPS varies from different bacteria 
strains and can not be estimated, molar ellipticity [θ] is not able to be calculated and the 
original CD absorption in mdeg is used as the Y-axis. (Bottom). Corresponding HT value (in 
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Volt) curve of LPS (P) and LPS (K) alone as plotted against wavelength in [nm]. Generally 
HT values which go beyond 500 V are unacceptable.  
 
Figure 3.2: CD spectrum of buffer (50 mM sodium phosphate, pH = 6.8) 
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Figure 3.3: (Top) CD spectra of peptide 23 alone (dashed line, black), peptide 23 with LPS 
vesicle from Pseudomonas aeruginosa (P) (solid line, red) and Klebsiella pneumoniae (K) 
(solid line blue) in phosphate buffer converted into molar ellipticity [θ], where the buffer 
baseline has been subtracted from the original spectrum of peptide alone, and the LPS signal 
has been subtracted from original peptide-LPS complex signal. Thus all three spectra shown 
at top represent peptide CD signals in different chemical environments. (Bottom) 
corresponding HT values which go beyond 500 V are unacceptable. 
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Figure 3.4: CD spectra of peptide 29 alone (dashed line, black), peptide 29 with LPS vesicle 
from Pseudomonas aeruginosa (P) (solid line, red) and Klebsiella pneumoniae (K) (solid line 
blue) in phosphate buffer converted into molar ellipticity [θ], where the buffer baseline has 
been subtracted from the original spectrum of peptide alone, and the LPS signal has been 
subtracted from original peptide-LPS complex signal. Thus all three spectra shown at top 
represent peptide CD signals in different chemical environments.  
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Figure 3.5: CD spectra of peptide 36 alone (dashed line, black), peptide 36 with LPS vesicle 
from Pseudomonas aeruginosa (P) (solid line, red) and Klebsiella pneumoniae (K) (solid line 
blue) in phosphate buffer converted into molar ellipticity [θ], where the buffer baseline has 
been subtracted from the original spectrum of peptide alone, and the LPS signal has been 
subtracted from original peptide-LPS complex signal. Thus all three spectra shown at top 
represent peptide CD signals in different chemical environments.  
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Figure 3.6: CD spectra of peptide 43 alone (dashed line, black), peptide 43 with LPS vesicle 
from Pseudomonas aeruginosa (P) (solid line, red) and Klebsiella pneumoniae (K) (solid line 
blue) in phosphate buffer converted into molar ellipticity [θ], where the buffer baseline has 
been subtracted from the original spectrum of peptide alone, and the LPS signal has been 
subtracted from original peptide-LPS complex signal. Thus all three spectra shown at top 
represent peptide CD signals in different chemical environments.  
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Figure 3.7: CD spectra of peptide 49 alone (dashed line, black), peptide 49 with LPS vesicle 
from Pseudomonas aeruginosa (P) (solid line, red) and Klebsiella pneumoniae (K) (solid line 
blue) in phosphate buffer converted into molar ellipticity [θ], where the buffer baseline has 
been subtracted from the original spectrum of peptide alone, and the LPS signal has been 
subtracted from original peptide-LPS complex signal. Thus all three spectra shown at top 
represent peptide CD signals in different chemical environments.  
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Figure 3.8: CD spectra of peptide 53 alone (dashed line, black), peptide 53 with LPS vesicle 
from Pseudomonas aeruginosa (P) (solid line, red) and Klebsiella pneumoniae (K) (solid line 
blue) in phosphate buffer converted into molar ellipticity [θ], where the buffer baseline has 
been subtracted from the original spectrum of peptide alone, and the LPS signal has been 
subtracted from original peptide-LPS complex signal. Thus all three spectra shown at top 
represent peptide CD signals in different chemical environments.  
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Discussion of CD spectra of peptide-LPS interaction 
    The y-axis unit of each set of the peptide alone and peptide-LPS (LPS subtracted) 
spectra has been converted into molar ellipticity [θ] from the original raw ellipticity θ data in 
millidegree; the advantage of using molar ellipticity is that it eliminates the concentration 
variance brought about by using different batches of peptide stock solutions. Thus it is more 
rigorous to compare spectral differences between the peptide alone and peptide-LPS. All the 
spectra shown above are on the same scale and the change of the peptide conformation can be 
observed and investigated. 
    Inspection of each peptide’s CD spectra shows that, firstly, the peptide conformation has 
changed upon mixing with LPS vesicles, from its native conformation in phosphate buffer, 
indicating peptide molecules indeed interact with LPS. This conformation change is 
presented through the shifts of the absorption wavelength and change of the CD intensity at 
the minima. Secondly, each peptide interacts with LPS from Pseudomonas aeruginosa (P) 
and Klebsiella pneumoniae (K) in a similar manner, which is supported by the fact that the 
shape, intensity, and position of the absorptions with LPS (P) and LPS (K) are very similar. It 
can be inferred that even though the two LPS species are very different in terms of specific 
sugar moiety sequence and lipid A chemical composition [46] [47], the peptide can not 
discriminate such variance and interacts with the two LPS species as if they are the same. At 
the same time, different peptides shows totally different spectra when interacting with the 
same LPS (P) or LPS (K). This shows it is the physicochemical properties of peptide and LPS, 
such as hydrophobicity and net surface charge, that determine the interaction behavior and 
thus the overall CD spectra shape of the peptides.  
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    What follows are qualitative discussions of conformational changes of each peptide 
shown by each set of CD spectra above: 
(1) Peptide 23 (Figure 3.3): The peptide spectrum shows negative bands at ~207 nm. By 
comparison, when LPS (P or K) is mixed with the peptide, absorption of the 207 nm band 
shifts to approximately 202 nm. The shoulder (~220-224 nm) shifts to longer wavelength 
~224-228 nm in the presence of LPS. This result indicates peptide 23 conformation changes 
compared with the original conformation. However, the percentage of original conformation 
change can not be estimated because of the introduction of the unnatural amino acids. 
(2) Peptide 29 (Figure 3.4): The peptide alone has an intense band at ~205 nm and shows a 
very weak shoulder at ~216 nm. When mixed with LPS, the intense band shifts to 
approximately 202 nm. Meanwhile, the shoulder remains at ~222 nm. This indicates peptide 
29 adopts a conformation which is different from that of peptide alone when LPS is added. 
(3) Peptide 36 (Figure 3.5): This peptide has a very similar binding trend to that seen with 
peptide 29. The shoulder at ~218 nm begins to show up when LPS is added, leading to an 
indication of conformation change. 
(4) Peptide 43 (Figure 3.6): Again, the 222 nm shoulder becomes apparent and the minimum 
at 209 nm is blue-shifted to ~203 nm, a case which is just similar with peptide 23, 29 and 36. 
Presumably it adopts a different conformation compared with the original conformation.  
(5) Peptide 46: the CD spectra of peptide with LPS are very weak and noisy and it’s difficult 
to see any conformational features. Thus spectra of peptide 46 are not shown.  
(6) Peptide 49 (Figure 3.7): Spectrum feature change is very similar to that of peptide 29, 
along with dramatic conformation change from the peptide alone. Once mixed with LPS 
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(either P or K), the negative peak at ~222 nm changes, at the same time a negative band 
around 195 nm appears in peptide-LPS spectra, indicating a dramatic conformational change. 
(7) Peptide 53 (Figure 3.8): The negative peak at ~207 nm of the peptide shifts to ~202 nm. 
One very tiny shoulder begins to show up around 225 nm, otherwise the trend of 
conformational change is still similar to peptide 23, 29, 36 and 43. But compared with other 
peptides that show a very significant change in the 225 nm band, peptide 53 shoulder change 
is hardly observable.  
(8) Peptide 56: the CD spectra of peptide with LPS are very weak and noisy and it’s difficult 
to see any conformational features. Thus spectra of peptide 56 are not shown. 
From the above, it can be concluded that different peptide residue sequences decide the 
difference of the physicochemical properties of the peptides. As a result, the CD spectra of 
peptides interacting with LPS vesicles also become different in terms of the shapes and 
intensities. The main objective of this project is to qualitatively correlate the CD spectral 
features of peptides with the physicochemical properties of peptides in an effort to further 
understand structure-activity relationships. 
As previously mentioned in Chapter One, the peptides used in this project consist of four 
key components: Tic-Oic dipeptide units, which reduce the overall peptide molecular 
flexibility; SPACER # 1, which defines the distance between the two Tic-Oic dipeptide units. 
(They are Glysine (G), β-Alanine (β-Ala) and GABA (γ-aminobutyric acid) for the eight 
peptides discussed above); SPACER # 2, which defines the distance between the peptide 
backbone and the positively charged side chain nitrogen atom as well as determining the 
overall charge density of the molecule. (These include Lysine (K), 2,3-diaminopropionic acid 
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(Dpr), 2,4-diaminobutanoic acid (Dab) and 2,5-diamino-pentanoic acid (Orn)); and finally 
amino acids with hydrophobic side chains, which are also substantial to give peptides the 
appropriate level of hydrophobicity that is important for peptide interacting with hydrophobic 
components of various liposomes, including both LPS and phospholipids. Such hydrophobic 
side chain species can be Phenylalanine (F), 4-fluorophenylalanine (Fpa) and 
4-Nitrophenylalanine (Nph). It can be expected that the interaction between peptides and LPS 
vesicles is a combined result of physicochemical properties of the four key components.  
Since the four key components are all variables which determine peptides’ 
physicochemical properties, it makes the comparative study much easier and more 
straightforward if all these variables are collected in a table so that we can simply focus on 
those important modules rather than reading through long peptide sequences. 
Table 3.2: SPACER #1, SPACER # 2, and hydrophobic residues for each peptide [5]. 
Peptide 
Numbe
r # 
Spacer # 1 Spacer #2 Hydrophobic 
23 
  
 
 
 
 
29 
GABA 
F 
K
G 
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36 
   
β-Ala 
43 
  Orn
46 
 
   
Fpa
Dpr 
 
 
49 Nph 
 
 
 
53 
Dab 
   
56 
R 
For the columns of SPACER #1 and SPACER # 2, lighter color indicates shorter carbon 
chains and darker color indicates longer. Thus for SPACER #1 the length of Gly＜β-Ala＜
GABA; for SPACER # 2 Dpr＜Dab＜Orn＜K. Arginine (R) is not in the comparison 
sequence for its special complex guanidinium distal end. For the column of hydrophobic 
residues, the pink color scale shows the substitution variance of p-substituted phenylalanine, 
from natural phenylalanine (F) to 4-Nitrophenylalanine (Nph).  
There are two important comparison groups in this part of investigation. One group 
 35 
 
includes 23, 29 and 36, which studies the effect of the length of the SPACER # 1, the other 
group includes 23, 43 and 53 to focus on SPACER # 2. Both groups keep the other variables 
constant.  
Spacer # 1 Spacer #2 Hydrophobic Peptide 
Number # 
 
23 
K
36 
 
G F 
β-Ala 
29 
GABA 
Table 3.3: Structural feature comparison of peptide # 23, # 36 and # 29 
 
Figure 3.9 CD spectra comparison of peptide 23, 29 and 36 with LPS (P) and (K) 
 36 
 
    The only variable among this group is the length of SPACER # 1 side chain, which is 
Glycine for 23, β-alanine for 36 and GABA for 29, respectively, and the length has been put 
in ascending order. The three residues here are very similar in chemical property except for 
small changes of hydrophobicity due to the different number of side chain –CH2- groups. All 
three peptides show negative shoulder minima at ~225 nm. The first minima of 23 and 29 are 
at shorter wavelength at ~ 203 nm compared with that of 36 at ~ 207 nm. Though not so 
dramatic, there is a positive correlation between the length of SPACER # 1 and the spectra 
shape at the first negative minima, indicating that as the length of SPACER # 1 increases, the 
peptide conformational flexibility possibly becomes higher and conformational change is 
more significant upon biding with LPS. 
    The other comparison group includes 23, 43 and 53, focusing on SPACER # 2 variation, 
is shown below: 
Spacer # 1 Spacer #2 Hydrophobic Peptide 
Number # 
 
 
53 
G F 
Dab
 
43 
Orn
 
23 
K
Table 3.4: Structural feature comparison of peptide # 23, # 43 and # 53 
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Figure 3.10 CD spectra comparison of peptide 23, 43 and 53 with LPS (P) and (K) 
    Peptide # 53 has the shortest SPACER # 2 side chain among the three. An interesting 
observation is that the CD spectra of # 23 and 43 both show second negative minima at ~ 225 
nm but 53 almost does not show such a minimum, which at least indicates that 23 and 43 
adopt different conformation compared with 53. However, with careful inspection of the 
spectra comparison, the correlation between SPACER # 2 side chain length and CD spectra 
minima feature is not so immediately intuitive. Thus the hydrophobicity (shown in table 7) of 
SPACER # 2 side chain must be considered as an important factor along with side chain 
length. Side chain of 53 is 2,4-diaminobutanoic acid (Dab) and it’s the shortest side chain 
among the three, the hydrophobicity is medium, thus the effect of side chain length 
overweighs hydrophobicity and 53 shows the least conformation flexibility upon binding 
with LPS. Peptide 23 has the longest side chain and highest hydrophobicity at the same time, 
thus the net effect of the two factors balances out and the spectrum lies between 43 and 53. 
With the similar consideration, peptide 43 has the most molecular flexibility among the three. 
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In summary, the net effect of SPACER # 2 side chain is complicated, the delocalization of 
positive charge and hydrophobicity balance mutually to determine the interaction between 
peptides and LPS. 
Table 3.5: The combined Consensus Scale (CCS) (hydrophobicity) (the 4th column) 
Amino acid Number of 
Carbons in 
side chain 
Distance (in 
Å) 
Hydrophobicity Total 
Hydrophobicity
in peptide 
 
1 2.56 -9.3 -55.8 
Dpr 
 
2 3.9 -9.5 -57.0 
Dab 
 
3 5.0 -9.0 -54.0 
Orn 
 
4 6.4 -9.9 -59.4 
K 
 
3 7.0 -10.0 -60.0 
R 
Therefore it is not one single factor that determines the binding property of the peptides 
with LPS, but instead it’s a result of a combination of factors. There are always at least three 
important factors that control the binding interactions between peptides and membrane 
models: (1) positive charge distribution of SPACER # 2 side chain, (2) overall molecular 
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hydrophobicity and (3) molecular flexibility of the peptide backbone which is primarily 
controlled by the physicochemical property of SPACER # 1. 
    Lastly, peptide 49 is relatively special in terms of CD spectra shape so it’s difficult to 
place it into any group and make comparisons. The only possible comparison is with peptide 
23, in which the only variable is the hydrophobic residue, a 4-Nitrophenylalanine (Nph). 
Spacer # 1 Spacer #2 Hydrophobic Peptide Number # 
 
23 
 
49 Nph 
Table 3.6: Structural feature comparison of peptide # 23 and # 49 
 
Figure 3.11: CD spectra comparison of peptide 23 and 49 with LPS (P) and (K) 
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The only structural difference of peptide 49 compared with 23 is the introduction of the 
nitro- group at the para- position of the phenylalanine benzene ring, and the nitro- group may 
change the electron distribution within the benzene ring of the phenylalanine and could 
consequently change the overall physicochemical property of the molecule. However, 
cautious consideration should be taken that even though the nitro- group is the only structural 
variance between the two peptides, we can not directly and largely attribute the CD spectra 
change of peptide 49 to the specific functional group. Due to the complex nature of 
peptide-LPS interactions, many other factors could also affect the interaction of 49 with LPS 
and result in a very different spectrum feature. 
Background and Discussion of 1H NMR study of peptide-LPS interaction 
    The CD data shown and discussed above clearly indicates that peptides indeed interact 
with LPS P and K with various conformation changes. However it should not stop at this 
point, since the structure of LPS is very complex and there are three components in a 
complete LPS membrane model: O-antigen, inner core oligosaccharide and the 
phospholipid-like lipid A. The first two components consist of sugars and more hydrophilic in 
the buffer environment but the lipid A contains several phospholipids-like acyl long chains 
which tend to be more hydrophobic. Thus one can expect peptide molecule to interact with 
any one of the three components, but the question is with which region of LPS the interaction 
is the most dominant? 
    1H NMR spectroscopy is a useful tool for structural determination of peptides adopting 
conformations in membrane model environment and follows the same strategy as NMR 
structure determination on soluble proteins [33]. A previous study [48] using 1D 1H NMR, 
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2D 1H TOCSY NMR and diffusion ordered (DOSY) NMR has shown the mechanisms of 
binding of these AMPs to SDS and DPC micelles are dependent on the physicochemical 
properties of the AMPs and the micelles. Peptide # 23 was used as an example compound in 
D2O sodium acetate buffer and the aromatic resonances was studied in the presence of SDS 
and DPC micelles. The 1H NMR results showed that the aromatic rings (phenylalanine) of 
peptide 23 are in very different chemical environment when mixed with SDS and DPC 
micelles in D2O sodium acetate buffer and this result is consistent with CD data of peptide 23 
with SDS and DPC [29]. 
    In a recent investigation by Hicks R. et al [53], 1D 1H NMR was used to investigate 
AMP-LPS interactions. There are two major reasons that advanced NMR techniques, such as 
TOCSY, can not be used to study these AMP-LPS interactions. Firstly at the concentrations 
of the peptides required to conduct 2D NMR experiments, the peptide-LPS and 
peptide-phospholipid mixtures precipitated in the buffer thus NMR signals were not detected 
for the peptide protons. Secondly, the incorporation of three Tic-Oic dipeptide units (these 
amino acids are secondary amides and therefore lack amide protons) into the sequence of 
these peptides, coupled with severe overlap of the side chain protons in the region around 
2.5- 1.0 ppm, makes the application of 2D experiments very difficult. 
    CD spectra of peptides with LPS (P) and LPS (K) have shown for each peptide it binds 
with two different lipopolysaccharide in a similar manner, and the only shared and conserved 
region of each of the two LPS is the lipid A portion, thus it suggests that the peptides are 
staying longer and interacting more strongly with the highly conserved lipid A region, rather 
than highly variable O-antigen and core oligosaccharide regions [53]. Dramatic reduction in 
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the peak heights of the NMR spectra in the region between 1.5-0.5 ppm was observed when a 
1.0 mg/mL sample of LPS (P) in the presence of 0.1 mg of peptide 23, 29, 43, 53 and 56 [53]. 
Since at this low concentration of peptide NMR signals of peptide protons can not be 
observed, the said peak heights reduction at 1.5-0.5 ppm should have come from LPS (P) 
after comparison with the 1H spectrum of LPS (P) alone. This region corresponds to the 
resonances of –CH2- acyl side chain protons of lipid A. This observation suggests a strong 
binding of peptides with the LPS (P) lipid A region, and further inspection of the entire NMR 
spectrum shows that the other regions of the spectrum remain relatively unchanged on 
addition of the peptides into LPS (P) solution, which also supports the conclusion that the 
binding between peptide and LPS (P) occurs in lipid A [53].  
    A similar peak heights reduction of –CH2- acyl side chain protons of lipid A was also 
observed in the spectra of LPS (K) with the addition of peptide, ranging approximately from 
1.8 to 0.7 ppm. Again the NMR signals of peptides can not be observed. This suggests that 
the peptides are interacting with the lipid A region of LPS (K) just like they interact with the 
lipid A region of LPS (P), a small chemical shift value change may come from tiny structure 
difference of LPS (K) lipid A from that of LPS (P). Although the peak height reduction of 
LPS (K) lipid A region is not as dramatic as was observed with the LPS (P), it still supports 
that peptides interact more strongly with lipid A region of both LPS (P) and LPS (K). 
    Hicks’ conclusion [53] of peptides interacting more strongly with lipid A acyl side chain 
can be supported by the results of Brandenburg, K et al. [49]. In this study a synthetic triacyl 
glucosamine monosaccharide lipid A part structures corresponding to the non-reducing 
moiety of bacterial lipid A was analyzed biophysically. Fourier-transform infrared 
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spectroscopy (FTIR) was used to characterize the gel-to-liquid crystalline phase transition of 
lipid A. The FTIR shows that the temperature dependence of the peak position of the 
symmetric stretching vibration νs(CH2) indicates a gel-to-liquid crystalline phase transition 
of the acyl chains. In another peptide-LPS interaction study by the same author [50], the 
peptide binds to LPS with a high affinity and induces a change in the lipid A region and 
suggested a hydrophobic interaction between the peptide and the hydrocarbon chain region of 
lipid A.  
    Lastly, the only uncertain aspect of the NMR study is the reason behind the peak heights 
reduction of lipid A –CH2- acyl side chain. Hicks R. et al [53] proposed that the phenomenon 
is the increase of the T1 relaxation rates of lipid A acyl chain protons. C. Le Guerneve et al 
[51] showed the incorporation of cholesterol into DMPC (dimyristoylphosphatidylcholine) 
has an effect on the high frequency vibrations that contribute to T1 relaxation inducing longer 
T1 relaxation. They further explained that cholesterol restricts the high frequency motions of 
the acyl chains thus increasing the molecular order of these regions compared to the pure 
lipid bilayer.. 
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Results of 1D 1H NMR  
AMP # Peak area normalized to LPS (P) alone 
23 38% 
29 38% 
43 36% 
53 29% 
56 39% 
 
Table 3.7: Changes in peak area of the proton resonances in the region of 1.5-0.5 ppm of the 
spectra of LPS (P) as a function of the addition of a specific peptide [53] 
AMP # Peak area normalized to LPS (K) alone 
23 81% 
29 80% 
43 93% 
53 89% 
56 81% 
Table 3.8: Changes in peak area of the proton resonances in the region of 1.8-0.7 ppm of the 
spectra of LPS (K) as a function of the addition of a specific peptide [53] 
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Figure 3.12: (Left) 1D 1H NMR of LPS (P) ONLY in 150 mM perdeuterated sodium acetate 
buffer at a pH of 5.64 in D2O; (Right) 1D 1H NMR of LPS (P) plus peptide 23 in the same 
buffer. All LPS and peptide concentrations in NMR study keep consistent. Blue arrow shows 
peak of carbohydrate (sugar moiety) protons in LPS (P) and red arrow shows peak of acyl 
side chain –CH2- protons in lipid A. All spectra have been processed into the same scale [53]. 
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 Figure 3.13: (Left) 1D 1H NMR of LPS (K) ONLY in 150 mM perdeuterated sodium acetate 
buffer at a pH of 5.64 in D2O; (Right) 1D 1H NMR of LPS (K) plus peptide 23 in the same 
buffer. All LPS and peptide concentrations in NMR study keep consistent. Blue arrow shows 
peak of carbohydrate (sugar moiety) protons in LPS (K) and red arrow shows peak of acyl 
side chain –CH2- protons in lipid A. All spectra have been processed into the same scale [53]. 
 
 
 
3.1.2 Liposome System Two and Three: Inner Membrane Phospholipid Models of 
Gram-negative Bacteria Pseudomonas aeruginosa and Klebsiella pnemoniae and 
complete Outer Membrane of the two strains-A comparative study 
    The inner membrane and the phospholipids components of outer membrane of 
Gram-negative bacteria mostly consist of phospholipids. The natural Pseudomonas 
aeruginosa lipid consists of 21% POPG, 60% POPE and 11% caridiolipin [52]. For Klebsiella 
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pnemoniae it consists of 5% POPG, 82% POPE and 6% caridiolipin [52]. POPC and POPE 
are zwitterionic and POPG, caridiolipin are all anionic. The total percent of anionic lipids for 
Pseudomonas aeruginosa and Klebsiella pneumoniae are 32% and 11%, respectively [5]. In 
this project, 59% POPC/21% POPG/20% POPE (mix P) is used to approximate the lipid 
composition (molar ratio) of Pseudomonas aeruginosa and 75% POPC/5% POPG/20% 
POPE (mix K) for Klebsiella pneumoniae. The highest percentage of POPE can reach is 
20% out of total lipid because we also tested that when the percentage goes beyond 20% 
dramatic precipitates can form when mix the lipid solution with peptide stock solution. 
    In this section, CD spectra of peptides in the presence of inner membrane composition 
(mix P and K) will be compared with CD spectra of peptides in the presence of complete 
outer membrane (LPS-mix P and K), in the presence of LPS only (P and K), as well as the 
CD spectra of peptide alone in the phosphate buffer. 
 
Results: CD spectra of peptide alone, peptide-mix (P or K) and peptide-LPS-mix (P or K). 
Buffer line has been subtracted from peptide alone spectra and any lipid composition (mix or 
LPS-mix complex) has been subtracted from peptide-lipid spectra so all show the CD 
spectra of peptides in different chemical environments. 
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Figure 3.14: (Top) CD spectra of phospholipid composition mix (P) and mix (K); (bottom) 
HT value curve of mix (P) and mix (K) in buffer. Millidegree is used as the CD data unit. 
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Figure 3.15: (Top) CD spectra of LPS-mix (P or K) complex alone in the phosphate buffer; 
(bottom) HT value curve of LPS-mix (P) and LPS (K)-mix (K) in buffer. Millidegree is used 
as the CD data unit. Due to the incorporation of LPS, CD negative band at ~ 200 nm is still 
observable. Thus subtraction of the lipid line from peptide-lipid line is always necessary, 
even though CD spectra of lipid models are very weak. 
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Figure 3.16: (Top) CD spectra of peptide 23 alone (dashed line, black), peptide 23 with 
inner membrane composition from Pseudomonas aeruginosa (P) (solid line, red) and 
Klebsiella pneumoniae (K) (solid line blue) in phosphate buffer converted into molar 
ellipticity [θ]. 
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(Bottom) CD spectra comparison of peptide 23 with all three lipid model systems: peptide 23 
alone in buffer (solid line, black), peptide 23 with LPS (P) and (K) (solid & dashed line, red), 
peptide 23 with LPS-mix (solid & dashed line, green) and with mix (solid & dashed, pink). 
 
 
Figure 3.17:(Top) CD spectra of peptide 29 alone (dashed line, black), peptide 29 with inner 
membrane composition from Pseudomonas aeruginosa (P) (solid line, red) and Klebsiella 
pneumoniae (K) (solid line blue) in phosphate buffer converted into molar ellipticity [θ]. 
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(Bottom) CD spectra comparison of peptide 29 with all three lipid model systems: peptide 29 
alone in buffer (solid line, black), peptide 29 with LPS (P) and (K) (solid & dashed line, red), 
peptide 29 with LPS-mix (solid & dashed line, green) and with mix (solid & dashed, pink). 
 
 
Figure 3.18 (Top) CD spectra of peptide 36 alone (dashed line, black), peptide 36 with inner 
membrane composition from Pseudomonas aeruginosa (P) (solid line, red) and Klebsiella 
pneumoniae (K) (solid line blue) in phosphate buffer converted into molar ellipticity [θ]. 
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(Bottom) CD spectra comparison of peptide 36 with all three lipid model systems: peptide 36 
alone in buffer (solid line, black), peptide 36 with LPS (P) and (K) (solid & dashed line, red), 
peptide 36 with LPS-mix (solid & dashed line, green) and with mix (solid & dashed, pink). 
 
Figure 3.19: (Top) CD spectra of peptide 43 alone (dashed line, black), peptide 43 with 
inner membrane composition from Pseudomonas aeruginosa (P) (solid line, red) and 
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Klebsiella pneumoniae (K) (solid line blue) in phosphate buffer converted into molar 
ellipticity [θ]. 
(Bottom) CD spectra comparison of peptide 43 with all three lipid model systems: peptide 43 
alone in buffer (solid line, black), peptide 43 with LPS (P) and (K) (solid & dashed line, red), 
peptide 43 with LPS-mix (solid & dashed line, green) and with mix (solid & dashed, pink). 
 
Figure 3.20: (Top) CD spectra of peptide 49 alone (dashed line, black), with inner 
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membrane composition from Pseudomonas aeruginosa (P) (solid line, red) and Klebsiella 
pneumoniae (K) (solid line blue) in phosphate buffer converted into molar ellipticity 
[θ].(Bottom) CD spectra comparison of peptide 49 with all three lipid model systems: peptide 
alone in buffer (solid line, black), with LPS (P) and (K) (solid & dashed line, red), with 
LPS-mix (solid & dashed line, green) and with mix (solid & dashed, pink). 
 
Figure 3.21: (Top) CD spectra of peptide 53 alone (dashed line, black), with inner 
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membrane composition from Pseudomonas aeruginosa (P) (solid line, red) and Klebsiella 
pneumoniae (K) (solid line blue) in phosphate buffer converted into molar ellipticity 
[θ].(Bottom) CD spectra comparison of peptide 53 with all three lipid model systems: peptide 
alone in buffer (solid line, black), with LPS (P) and (K) (solid & dashed line, red), with 
LPS-mix (solid & dashed line, green) and with mix (solid & dashed, pink). 
 
Discussion 
    For the individual peptide, its three sets of CD spectra of interacting with three different 
membrane model compositions (LPS only, mixed phospholipid and LPS-phospholipid 
complex) are compared in one figure. Firstly when red lines (with LPS only) and green lines 
(with LPS-mix complex) are compared, it is apparent that each peptide interacts with the two 
models differently, which reveals an important information that LPS and LPS-mix complex 
have become two different chemical environments. Additionally, the spectra of peptide with 
LPS-mix complex (green) can not be obtained from simple spectra addition of the peptide 
with LPS only (red) and with mix only (pink). Thus it suggests that LPS and phospholipid 
have been incorporated together to make a LPS-mix SUV. It can be inferred, but can not be 
proved, under current experimental circumstances of this project, that the outer leaflet of the 
SUVs will contain a higher percentage of LPS as compared to the inner leaflet will contain 
almost exclusively phospholipids, there is no direct solid evidence that LPS is not 
incorporated in inner leaflet of membrane either. However, even if this is not the case and the 
LPS is randomly distributed over both the inner and outer leaflets, at least it suggests that 
LPS and phospholipids are incorporated to make a new liposome which is not the simple 
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physical mixture of the two. It still can be regarded as a combined effect of LPS and 
phospholipids on peptide binding. Thus this discussion is qualitative analysis of CD spectra. 
    Secondly, for each peptide, the shapes of spectra of peptide with phospholipid model, 
mix (P) (red) and mix (K) (blue), are similar in shape but are both different with spectrum of 
peptide alone in buffer, supporting that peptide changes conformation when it interacts with 
an inner membrane model of bacteria. For mix (P), there is a good positive correlation 
between the extent of the side chain positive charge delocalization and the intensity (23(Lys) 
>43(Orn) >53(Dab) >56(Arg) >46(Dpr) )of the CD spectra.  For these peptides the first 
negative peak values in the presence of only phospholipid are blue-shifted compared to the 
LPS-containing SUVs by about 2-4 nm, indicating a small change in the conformations upon 
binding with mix (P). 
    When CD spectra of the same peptides interacting with mix (K) and LPS (K)-mix (K) 
are compared, useful information can be extracted about the conformational change of 
peptides traveling from the outer membrane to the inner membrane. For example, CD spectra 
of peptide 43 with mix (K) (pink dashed line in 43 comparison set) and LPS (K)-mix (K) 
(green dashed line in # 43 comparison set) are different both in intensity (the former is less 
intense than the latter) and shape, indicating peptide 43 changes conformation while 
migrating from the outer membrane to the inner membrane, and the interaction with the outer 
membrane model LPS (K)-mix (K) is stronger. A similar trend is also observed in peptide 53 
interacting with complete outer membrane of LPS-mix (P and K) and with inner membrane 
of mix (P and K).  
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The comparison trend (red lines in bottom spectra) of each peptide interacting with LPS 
(P)-mix (P) and LPS (K)-mix (K) is complicated. For some peptides, such as 23 and 53, the 
molecular flexibility in the presence of LPS (K)-mix (K) is greater than with LPS (P)-mix (P) 
and for 43, flexibility and conformation with both models are almost the same. Such scenario 
is probably brought by the introduction of phospholipids into LPS. More specifically, it is 
partially due to surface charge difference between two phospholipid models. Mix (P) has 
21% of the anionic lipid POPG while mix (K) has only 5% POPG. The more essential reason 
behind the complexity, of course, lies in the physicochemical properties of peptide SPACER 
#2. 
 
Figure 3.22: CD spectral comparison of all peptide interacting with complete outer 
membrane models of Pseudomonas aeruginosa (solid lines) and Klebsiella pneumoniae 
(dashed lines). 
It is immediately obvious that for peptide 43 (black) the interaction with both models 
are almost the same. The hydrophobicity of the Orn residues of 43 is the highest (-9.0) of the 
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SPACER#2 residues, while the charge delocalization is the second lowest. Contributions 
from hydrophobicity and the extent of the positive charge delocalization of SPACER#2 side 
chain and the two factors balance out to make the CD spectra of 43 with both models almost 
the same. Such a phenomenon is also observed in 49 (yellow).  
It can be concluded, by studying CD spectra together with the consideration of the 
physicochemical properties of the SPACER, that the binding of peptides with the complete 
outer membrane models of Pseudomonas aeruginosa and Klebsiella pneumoniae does not 
simply depend on electrostatic interactions. The binding process is a complex balance 
between electrostatic and hydrophobic effects which makes each peptide interact with the two 
models differently. However, a precise correlation between peptide physicochemical 
properties and conformational change is very challenging under the current experimental 
technique limitations. 
 
3.2 Proposed Mechanism of AMPs Interacting with Gram-Negative Bacteria Cell Wall 
and Antimicrobial Activities of AMPs towards Pseudomonas aeruginosa and Klebsiella 
pneumoniae 
    After collecting all conformational change information from peptides interacting with 
the three membrane models, we proposed a possible mechanism of action towards 
Gram-negative bacteria cell membrane in a recent publication [53]. There are eight 
consecutive steps for a peptide molecule to travel through and bind with a cell membrane. 
Step A shows the initial binding of the peptide from the aqueous extracellular environment to 
the O-antigen, the outer component of LPS. Step B shows the transport of the AMP from the 
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O-antigen, through the core oligosaccharide, to the surface of Lipid A. This is also the time 
when the peptide interacts with the lipid A acyl side chains. Step C represents the transport of 
the peptide through lipid A of the LPS to the phospholipid component of the inner leaflet. In 
Step D, the peptide goes across the phospholipid layer of the inner leaflet. Step E represents 
the conformational changes that may occur in the periplasmic space between the outer and 
inner membranes.  Step F represents the binding and conformational changes associated 
with a single peptide molecule interacting with the surface of the phospholipids of the inner 
membrane outer leaflet. Step G represents the oligomerization of peptide molecules 
interacting with the surface of the phospholipids of the outer leaflet of the inner membrane 
prior to insertion into the membrane. Step H [29] represents the transition from the surface 
bound state to the membrane inserted state which results in disruption of the inner membrane.   
 
A 
B 
LPS 
C 
Outer membrane 
E D 
F G H 
Inner membrane 
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Figure 3.23: A cartoon representation showing the proposed binding and transport 
mechanism of a peptide with the outer and inner membranes of Gram-negative bacteria 
 
    CD spectroscopy is a powerful tool for studying the conformational changes of optically 
active compounds when they bind to other ligand molecules. However this biophysical 
technique can not give detailed structural information like NMR. Though it is attempting to 
try correlating the peptide binding behavior represented in CD spectra with the antimicrobial 
activity, the action mechanism of peptides towards pathogenic microbes is very sophisticated. 
One single factor, side chain positive charge density for instance, is far from sufficient to 
fully account for specific peptide activity.  
Pseudomonas aeruginosa PAO1 Klebsiella pneumoniae BAMC 
07-18 
 
Peptide # MIC (μg/mL) MBC (μg/mL) MIC (μg/mL) MBC (μg/mL) 
23 100 100 100 100 
29 ＞100 ＞100 100 100 
36 ＞100 ＞100 ＞100 ＞100 
43 50 50 50 50 
46 25 50 12.5 25 
49 50 100 50 50 
53 12.5 12.5 12.5 12.5 
56 100 ＞100 50 100 
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Table 3.9: In vitro susceptibility of antimicrobial peptides toward Pseudomonas aeruginosa 
and Klebsiella pneumoniae [5] 
    From the MIC and MBC data of the eight investigated peptides, the peptides probably 
interact with LPS (P) and (K) similarly because for each peptide relevant concentrations 
toward the two strains are very close. This has been supported by the similar intensity and 
shape of CD spectra of peptides binding to LPS (P) and (K). Secondly, among the eight 
peptides, peptides 46 and 53 are relatively more active than the others. Previous CD studies 
in section 3.1.2 have shown that the two peptides bind with LPS-mix more strongly than 
binding with the inner membrane model mix only, and within the process of peptide binding 
with the outer membrane, the interaction between peptide and lipid A region is more crucial 
for membrane disruption [51]. Thus, lower MIC and MBC concentrations of peptide 46 and 
53 can impart better perturbation on the lipid A region than the other less active peptides in 
the list. 
 
Final Conclusion 
    (1) The interactions between the peptides and membranes are defined by the 
complementary effects of several essential physicochemical properties of the peptides. 
Delocalization of positive charge density of the basic amino side chains which is controlled 
by SPACER # 2; molecular flexibility of the peptide backbone and overall hydrophobicity 
which is controlled by SPACER # 1 and # 2 together. The relative contribution of each of 
these key physicochemical properties depends on the composition of the model system 
investigated (i.e. the percentage of anionic lipids). 
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    (2) The peptides show a higher partition coefficient for the lipid A region than for the 
O-antigen or core oligosaccharide regions of the LPS, which is supported by 1 D 1H NMR.  
(3) Incorporation of phospholipids into the LPS-containing phospholipid SUVs results 
in pronounced changes in the conformation of the bound peptides.  
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